BCAN's Patient Handbook - Bladder Cancer Basics for the Newly Diagnosed



Donate Now to Support the Bladder Cancer Advocacy Network



Join The Online Bladder Cancer Support Community



The Bladder Cancer Advocacy Network (BCAN) is proud to be a Marine Corps Marathon Charity Partner!
  • BCAN has been allocated guaranteed entries for the 38th Annual Marine Corps Marathon to be held on October 27, 2013;
  • We are building “Team BCAN” to not only run in the event and raise awareness, but also to raise needed funds for medical research and patient education.
  • Join “Team BCAN” and have an official slot in the MCM by contacting Veronica Hunter at vhunter@bcan.org
  • No federal or Marine Corps endorsement is implied.
  • abfradet.jpg
    Yves Fradet, M.D., FRCSC
    Professor of Surgery
    Universite Laval

    Dr Yves Fradet graduated from Laval University (Quebec, Canada) in 1981, and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center, with Drs Willet Whitmore and Lloyd Old. Since 1983, he has headed a research laboratory at the Laval University Cancer Research Centre at the University hospital, where he is also director of the urologic oncology section. He is a member of many national and international societies, and is often invited as a guest speaker at national and international meetings, as a visiting professor, and as a consultant to many organizations. He was the founding chairman of the Canadian Urologic Oncology Group from 1988 to 1995. He has been the chairman of the department of surgery at Laval University since 2000. He has authored over 207 publications and book chapters, and 370 abstracts.

    Dr Fradet’s research activities involve translational laboratory research in tumour immunology; molecular biology of bladder and prostate cancer, and its applications to new diagnostics and treatments; epidemiological studies in bladder and prostate cancers; and clinical trials in prostate cancer, and other genitourinary cancers. Dr Fradet also has a very active practice in urologic oncology and clinical trials.